Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Jazz Pharmaceuticals' Ziihera Shows 3-Year Survival Benefit in Gastroesophageal Cancer

Jazz Pharmaceuticals' Ziihera Shows 3-Year Survival Benefit in Gastroesophageal Cancer

MT newswireMT newswire2026/10/23 14:50
10:50 AM EDT, 10/23/2026 (MT Newswires) -- Jazz Pharmaceuticals (JAZZ) said updated phase 3 results showed nearly 40% of patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma were alive after three years when treated with Ziihera, tislelizumab and chemotherapy. Ziihera plus chemotherapy also delivered a statistically significant and clinically meaningful overall survival benefit, reducing the risk of death by 24% compared with trastuzumab plus chemotherapy, Jazz said Friday in a statement. Median overall survival reached 27 months with Ziihera plus tislelizumab and chemotherapy versus 19.6 months with trastuzumab plus chemotherapy, the company said. The safety profiles of both Ziihera-containing regimens were consistent with the first interim analysis, supporting the tolerability of prolonged treatment, the company said. Price: 212.16, Change: -2.49, Percent Change: -1.16
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

While the industry faces turmoil, "Nvidia-backed" Nscale presses ahead for NYSE listing! New IPO prospectus reveals 1,344% surge in revenue but a quarterly net loss of $1.69 billion

Nscale, a "New Cloud" provider backed by Nvidia, submitted its latest filing for an initial public offering (IPO) in the United States on Thursday.

智通财经•2026/11/13 00:41

AI capital expenditures peak as global stock market profits"shift gears"! Goldman Sachs outlines three major themes for 2027

Goldman Sachs Portfolio Strategy Research Department pointed out that as the artificial intelligence investment boom peaks, global stock market earnings growth is expected to decline by more than half in 2027. However, recent valuation declines have created attractive entry points for long-duration technology growth stocks.

智通财经•2026/11/13 00:37

Nvidia (NVDA.US) CEO resigns, causing U.S. stocks to fall; Dow Jones drops 189 points

The resignation of Nvidia CEO Jensen Huang has triggered management turmoil, coupled with espionage rumors, leading to a broad decline in the New York stock market on the 12th. The Dow Jones Industrial Average closed down 189.40 points, with the S&P 500 and the Nasdaq Composite also posting losses, and small and mid-cap stocks experiencing the largest declines. Although the long-term outlook for AI remains unchanged, individual corporate governance risks are significantly weighing on the sentiment of the technology sector, driving funds to shift toward competitors and non-tech blue-chip stocks.

智通财经•2026/11/13 00:37